T

he foundational patents on the CRISPR-Cas9 technology remain hung up in an ugly legal fight. But applications for new patents on specific uses of the genome-editing system continue to be filed.

The latest, published on Thursday but first filed in 2013, covers the use of CRISPR-Cas (it’s broader than just Cas9) in what are called nucleotide repeat disorders — basically, inherited diseases in which DNA stutters: A gene includes hundreds, instead of just a few, repeats of strings of letters such as CAG or CGG.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X